Hiroki Ono

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.

Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 25, 2025

Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2 Isoforms Blood Test.

Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2 Isoforms Blood Test.

Journal: Clinical and translational gastroenterology

Published: December 15, 2024

Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.

Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: November 17, 2023

Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease.

Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease.

Journal: PloS one

Published: August 19, 2023

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.

Journal: PloS one

Published: May 24, 2023

Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.

Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.

Journal: Hepatology communications

Published: February 26, 2022

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial.

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial.

Journal: Nutrients

Published: April 29, 2021

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.

Journal: Therapeutic advances in endocrinology and metabolism

Published: December 15, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026